Sun Pharmaceutical Industries has received USFDA approval for the drug tildrakizumab-asmn which is used for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. The drug selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor leading to inhibition of the release of pro-inflammatory cytokines and chemokines.
Company Profile : Sun Pharmaceutical Industries Ltd
Leave a Reply